Corbus Pharmaceuticals Holdings, Inc. (CRBP): Depreciation & Amortization
$233.0K
Year ended 2025-12-31
$199.0K
Trailing 12 months to 2026-06-30
-32.7%
3-year compound annual growth
-27.0%
5-year compound annual growth
+18.2%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $233.0K | -60.4% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $588.0K | -8.3% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $641.0K | -16.0% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $763.0K | -23.7% | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | $999.8K | -11.0% | 2023-03-07, From 2021-01-01 |
| 2020-12-31 | $1.12M | +52.0% | 2022-03-08, From 2020-01-01 |
| 2019-12-31 | $739.4K | +49.7% | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | $493.9K | +93.2% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $255.7K | +191.6% | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $87.7K | +99.5% | 2018-03-12, From 2016-01-01 |
| 2015-12-31 | $43.9K | n/a | 2018-03-12, From 2015-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $233.0K | -60.4% |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $97.0K | n/a |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $2.48M | +60.2% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $24.0K | -97.1% |
| PepGen Inc. (PEPG) | 2025-12-31 | $1.40M | -6.7% |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $76.4K | -15.9% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $454.0K | -43.7% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $548.0K | -23.7% |
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | $1.25M | +15.2% |
Compare CRBP, CLYM, GYRE, GOSS side by side · Screen every company in Pharmaceutical Preparations ↗